ISR Holding: SARS-CoV-2 vaccine study approved by Bangladesh BMRC
Research Note
2022-07-01
14:08
Redeye endorses ISR receiving approval from Bangladesh BMRC to conduct a clinical phase I/II study with the company’s COVID-19 vaccine.
EL
Ethel Luvall
Disclosures and disclaimers